Literature DB >> 6086191

Studies on the mechanism of action of the hypotensive effect of ketanserin.

J F Marwood, G S Stokes.   

Abstract

Ketanserin, 0.01-3.0 mg/kg i.v., was found to cause a dose-related fall in blood pressure in anaesthetized rats. However, these decreases were only significant after 1 and 3 mg/kg doses. Subsequent administration of prazosin, 0.2 mg/kg i.v., had no significant effect on blood pressure. In the presence of ketanserin 3 mg/kg, plus prazosin 0.2 mg/kg, adenosine caused a significant dose-dependent fall in blood pressure in anaesthetized rats. Methysergide, 1 mg/kg i.v., significantly attenuated the blood pressure responses to serotonin in anaesthetized rats whereas ketanserin (1 and 3 mg/kg) had no overall effect on serotonin responses. Ketanserin, 1 and 3 mg/kg i.v., was found to antagonize the pressor effects of phenylephrine and reverse the pressor effects of adrenaline in anaesthetized rats. Responses to angiotensin II were not significantly affected by ketanserin. These results suggest that ketanserin lowers blood pressure in anaesthetized rats by blockade of alpha-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086191     DOI: 10.1111/j.1440-1681.1984.tb00249.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.

Authors:  Roberta Galeazzi; Luca Massaccesi; Francesco Piva; Giovanni Principato; Emilioano Laudadio
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

Review 3.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.